We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Stock Moves -0.99%: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed the most recent trading day at $691.47, moving -0.99% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.26%. Meanwhile, the Dow lost 0.8%, and the Nasdaq, a tech-heavy index, lost 0.44%.
Prior to today's trading, shares of the biopharmaceutical company had gained 12.9% over the past month. This has outpaced the Medical sector's gain of 4.88% and the S&P 500's gain of 6.07% in that time.
Investors will be hoping for strength from Regeneron as it approaches its next earnings release. The company is expected to report EPS of $9.39, down 5.06% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.98 billion, up 18% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $44.16 per share and revenue of $11.87 billion. These results would represent year-over-year changes of -40.85% and -26.14%, respectively.
It is also important to note the recent changes to analyst estimates for Regeneron. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.89% lower. Regeneron is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 15.81 right now. Its industry sports an average Forward P/E of 23.91, so we one might conclude that Regeneron is trading at a discount comparatively.
Investors should also note that REGN has a PEG ratio of 1.22 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.22 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Stock Moves -0.99%: What You Should Know
Regeneron (REGN - Free Report) closed the most recent trading day at $691.47, moving -0.99% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.26%. Meanwhile, the Dow lost 0.8%, and the Nasdaq, a tech-heavy index, lost 0.44%.
Prior to today's trading, shares of the biopharmaceutical company had gained 12.9% over the past month. This has outpaced the Medical sector's gain of 4.88% and the S&P 500's gain of 6.07% in that time.
Investors will be hoping for strength from Regeneron as it approaches its next earnings release. The company is expected to report EPS of $9.39, down 5.06% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.98 billion, up 18% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $44.16 per share and revenue of $11.87 billion. These results would represent year-over-year changes of -40.85% and -26.14%, respectively.
It is also important to note the recent changes to analyst estimates for Regeneron. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.89% lower. Regeneron is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 15.81 right now. Its industry sports an average Forward P/E of 23.91, so we one might conclude that Regeneron is trading at a discount comparatively.
Investors should also note that REGN has a PEG ratio of 1.22 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.22 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 161, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.